Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Cidara Therapeutics

DB:20D
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
20D
DB
$99M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • Cidara Therapeutics has significant price volatility in the past 3 months.
20D Share Price and Events
7 Day Returns
4.6%
DB:20D
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-10.8%
DB:20D
-7.4%
DE Biotechs
-14.2%
DE Market
20D Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cidara Therapeutics (20D) 4.6% 5.6% -33.1% -10.8% -63.9% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 20D underperformed the Biotechs industry which returned -7.4% over the past year.
  • 20D outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
20D
Industry
5yr Volatility vs Market
Related Companies

20D Value

 Is Cidara Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cidara Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cidara Therapeutics.

DB:20D Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:20D
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (11.81%))
1.098
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.098 * 5.44%)
5.58%

Discounted Cash Flow Calculation for DB:20D using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cidara Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:20D DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.58%)
2020 -63.89 Analyst x1 -60.51
2021 -81.34 Analyst x2 -72.96
2022 -81.32 Analyst x2 -69.09
2023 -43.10 Analyst x2 -34.68
2024 47.83 Analyst x2 36.45
2025 70.26 Est @ 46.89% 50.72
2026 93.24 Est @ 32.71% 63.75
2027 114.47 Est @ 22.78% 74.13
2028 132.59 Est @ 15.83% 81.32
2029 147.13 Est @ 10.96% 85.47
Present value of next 10 years cash flows $154.00
DB:20D DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $147.13 × (1 + -0.39%) ÷ (5.58% – -0.39%)
$2,454.14
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,454.14 ÷ (1 + 5.58%)10
$1,425.64
DB:20D Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $154.00 + $1,425.64
$1,579.64
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,579.64 / 40.51
$38.99
DB:20D Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:20D represents 0.92245x of NasdaqGM:CDTX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.92245x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 38.99 x 0.92245
€35.97
Value per share (EUR) From above. €35.97
Current discount Discount to share price of €2.26
= -1 x (€2.26 - €35.97) / €35.97
93.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cidara Therapeutics is available for.
Intrinsic value
>50%
Share price is €2.26 vs Future cash flow value of €35.97
Current Discount Checks
For Cidara Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cidara Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cidara Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cidara Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cidara Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:20D PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.41
NasdaqGM:CDTX Share Price ** NasdaqGM (2020-04-08) in USD $2.45
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cidara Therapeutics.

DB:20D PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CDTX Share Price ÷ EPS (both in USD)

= 2.45 ÷ -1.41

-1.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cidara Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cidara Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cidara Therapeutics's expected growth come at a high price?
Raw Data
DB:20D PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
27%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cidara Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cidara Therapeutics's assets?
Raw Data
DB:20D PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.12
NasdaqGM:CDTX Share Price * NasdaqGM (2020-04-08) in USD $2.45
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:20D PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CDTX Share Price ÷ Book Value per Share (both in USD)

= 2.45 ÷ 1.12

2.19x

* Primary Listing of Cidara Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cidara Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cidara Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cidara Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

20D Future Performance

 How is Cidara Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cidara Therapeutics expected to grow at an attractive rate?
  • Cidara Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Cidara Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Cidara Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:20D Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:20D Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 27%
DB:20D Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 47.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:20D Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:20D Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 124 40 35 4
2023-12-31 61 -11 -25 4
2022-12-31 24 -51 -61 4
2021-12-31 4 -67 -76 5
2020-12-31 12 -63 -68 5
2020-04-09
DB:20D Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 21 -29 -41
2019-09-30 19 -27 -39
2019-06-30 -56 -56
2019-03-31 -59 -69
2018-12-31 -57 -69
2018-09-30 -53 -70
2018-06-30 -54 -69
2018-03-31 -50 -59
2017-12-31 -50 -56
2017-09-30 -52 -57
2017-06-30 -46 -57
2017-03-31 -43 -52

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cidara Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Cidara Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:20D Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Cidara Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:20D Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.42 1.27 -0.42 4.00
2023-12-31 -0.63 -0.49 -0.89 4.00
2022-12-31 -1.32 -1.14 -1.48 5.00
2021-12-31 -1.54 -1.07 -1.95 6.00
2020-12-31 -1.34 -0.85 -1.76 6.00
2020-04-09
DB:20D Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.41
2019-09-30 -1.53
2019-06-30 -2.14
2019-03-31 -2.58
2018-12-31 -2.76
2018-09-30 -3.05
2018-06-30 -3.40
2018-03-31 -3.19
2017-12-31 -3.18
2017-09-30 -3.39
2017-06-30 -3.55
2017-03-31 -3.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cidara Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cidara Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cidara Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

20D Past Performance

  How has Cidara Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cidara Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cidara Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cidara Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cidara Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cidara Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cidara Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:20D Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 20.92 -41.09 16.24
2019-09-30 19.10 -39.41 15.39 49.14
2019-06-30 -56.07 14.26 47.74
2019-03-31 -69.16 14.27 48.61
2018-12-31 -69.35 14.14
2018-09-30 -70.43 13.82 10.23
2018-06-30 -69.07 13.46 44.21
2018-03-31 -59.08 13.35 45.78
2017-12-31 -55.73 12.90
2017-09-30 -56.69 12.71 43.90
2017-06-30 -56.66 13.23 43.47
2017-03-31 -51.77 13.20 38.75
2016-12-31 -48.17 12.74 35.70
2016-09-30 -43.64 12.06 31.95
2016-06-30 -40.59 10.89 29.99
2016-03-31 -35.25 9.74 25.73
2015-12-31 -32.19 8.84 23.48
2015-09-30 -26.97 7.65 19.39
2015-06-30 -21.12 6.54 14.61
2015-03-31 -17.92 4.82 11.37
2014-12-31 -11.89 3.31 6.71
2014-09-30 -7.65 2.19 3.47
2013-12-31 -1.34 0.27 0.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cidara Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cidara Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cidara Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cidara Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cidara Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

20D Health

 How is Cidara Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cidara Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cidara Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cidara Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cidara Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cidara Therapeutics Company Filings, last reported 3 months ago.

DB:20D Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 37.84 9.97 50.27
2019-09-30 48.96 9.96 73.82
2019-06-30 31.78 9.95 44.57
2019-03-31 43.86 9.94 57.41
2018-12-31 59.14 9.93 74.56
2018-09-30 69.93 9.92 88.27
2018-06-30 82.14 9.91 103.20
2018-03-31 50.92 9.89 66.19
2017-12-31 59.74 9.87 75.31
2017-09-30 50.57 9.85 64.15
2017-06-30 61.26 9.83 78.01
2017-03-31 75.99 9.81 90.09
2016-12-31 88.18 9.79 104.62
2016-09-30 73.92 0.00 79.31
2016-06-30 84.81 0.00 87.09
2016-03-31 95.08 0.00 96.66
2015-12-31 103.91 0.00 107.51
2015-09-30 112.63 0.00 114.42
2015-06-30 120.86 0.00 122.30
2015-03-31 56.94 0.00 58.12
2014-12-31 21.10 0.00 22.80
2014-09-30 25.57 0.00 25.57
2013-12-31 -1.40 1.48 0.19
  • Cidara Therapeutics's level of debt (26.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Cidara Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cidara Therapeutics has sufficient cash runway for 1.8 years based on current free cash flow.
  • Cidara Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.3% each year.
X
Financial health checks
We assess Cidara Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cidara Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

20D Dividends

 What is Cidara Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cidara Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Cidara Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cidara Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cidara Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:20D Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:20D Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cidara Therapeutics has not reported any payouts.
  • Unable to verify if Cidara Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cidara Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cidara Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Cidara Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Cidara Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cidara Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cidara Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

20D Management

 What is the CEO of Cidara Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Stein
COMPENSATION $1,363,737
AGE 64
TENURE AS CEO 6.3 years
CEO Bio

Dr. Jeffrey L. Stein, also known as Jeff, Ph.D., has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein was Principal Financial Officer at Cidara Therapeutics, Inc. Dr. Stein serves as Principal Scientist of Verenium Corporation. He is Scientific Advisor of Spero Therapeutics, Inc. Dr. Stein served as Senior Vice President of Educational Strategy at MedCases, LLC. Dr. Stein served as a Principal Scientist of BASF Enzymes LLC. He also serves as a Faculty Research Associate at UC San Diego's Center for Marine Biotechnology and Biomedicine and in the Marine Biology Research Division of Scripps Institution of Oceanography. Dr. Stein was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein served as the President and Chief Executive Officer of Trius Therapeutics Inc. since February 2007. From 2005 to 2010, he was a Venture Partner at Sofinnova Ventures, Inc. He joined the Sofinnova Ventures, Inc. in May 2005 as a Kauffman Fellow at the Sofinnova Ventures till 2007 and was a part of the life science team. He works with Sofinnova's life science investment team to identify San Diego-based investment opportunities in the area of biopharmaceutical clinical development and advises the firm's life science portfolio companies on clinical and business matters. He has held senior scientific and management positions in the biopharmaceutical industry for the past 20 years. From 1999 to 2005, Dr. Stein was the Founder & Chief Scientific Officer of Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005 and also served as its Executive Vice President. He served as a Principal Scientist and head of the anti-infectives discovery team at Diversa Corporation. From 1995 to 1999, Dr. Stein was a scientist with the Diversa Corporation. From 1993 to 1995, he was a Principal Investigator at the Agouron Institute, where his laboratory developed techniques to clone and characterize microbial gene pathways. He serves on the Board of Rx3 Pharmaceuticals and Quorex. He has been a Director of IDEAYA Biosciences, Inc. since October 2015. He has been a Director of Paratek Pharmaceuticals, Inc. since October 30, 2014. He served as an Executive Director of Trius Therapeutics, Inc. since 2005. He served as a Director of Quorex Pharmaceuticals, Inc. He served as Director of Venture Development at University of California - San Diego. He was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein has also served as Director of Venture Development at UC San Diego from 2005 to 2006. He is considered an authority on the cloning and expression of microbial gene pathways and is a frequent invited lecturer on this topic at research and governmental institutions worldwide. he was a past member of the National Research Counsel’s Task Group for the Limits of Organic Life in Planetary Systems, a member of the President’s Panel on National Ocean Exploration Strategy and a past member of the National Science Foundation’s Engineering Center Site Review Team. Among the various honors he has received is the Thomas Alva Edison Patent Award. Dr. Stein holds a Ph.D. in Biochemistry and Marine Biology from the University of California, San Diego. Dr. Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology. Dr. Stein obtained a B.S. in Marine Biology and an M.S. in Biology from California State University, Long Beach. He is Graduate Student Researcher Fellow at UCSD.

CEO Compensation
  • Jeff's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cidara Therapeutics management team in years:

3.7
Average Tenure
48
Average Age
  • The tenure for the Cidara Therapeutics management team is about average.
Management Team

Jeff Stein

TITLE
President
COMPENSATION
$1M
AGE
64
TENURE
6.3 yrs

Paul Daruwala

TITLE
COO & Chief Commercial Officer
COMPENSATION
$662K
AGE
50
TENURE
2.3 yrs

Taylor Sandison

TITLE
Chief Medical Officer
COMPENSATION
$678K
AGE
47
TENURE
3.6 yrs

Kevin Forrest

TITLE
Founder and Chief Strategy Officer
COMPENSATION
$613K
AGE
42
TENURE
3.8 yrs

Jamie Levine

TITLE
Chief Financial Officer
AGE
48
TENURE
1.3 yrs

Brady Johnson

TITLE
Principal Accounting Officer
TENURE
1.7 yrs

Jessica Oien

TITLE
General Counsel & Secretary
AGE
48
TENURE
1.6 yrs

Ken Bartizal

TITLE
Chief Development Officer
COMPENSATION
$335K
AGE
68
TENURE
5.8 yrs

Jim Balkovec

TITLE
Senior Vice President of Research
TENURE
5.2 yrs

Neil Abdollahian

TITLE
Chief Business Officer
COMPENSATION
$946K
AGE
46
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the Cidara Therapeutics board of directors in years:

3.6
Average Tenure
64
Average Age
  • The tenure for the Cidara Therapeutics board of directors is about average.
Board of Directors

Dan Burgess

TITLE
Independent Chairman of the Board
COMPENSATION
$99K
AGE
57
TENURE
0.8 yrs

Jeff Stein

TITLE
President
COMPENSATION
$1M
AGE
64
TENURE
6.3 yrs

Ted Schroeder

TITLE
Independent Director
COMPENSATION
$98K
AGE
64
TENURE
6 yrs

Tim Franson

TITLE
Independent Director
COMPENSATION
$91K
AGE
67
TENURE
5.1 yrs

Chrysa Mineo

TITLE
Independent Director
COMPENSATION
$179K
AGE
54
TENURE
2.1 yrs

David Gollaher

TITLE
Independent Director
COMPENSATION
$99K
AGE
69
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Jan 20 Sell Jessica Oien Individual 02. Jan 20 02. Jan 20 -834 €3.45 €-2,878
06. Jan 20 Sell Paul Daruwala Individual 03. Jan 20 03. Jan 20 -2,340 €3.06 €-7,163
06. Jan 20 Sell Neil Abdollahian Individual 03. Jan 20 03. Jan 20 -2,340 €3.06 €-7,163
03. Oct 19 Sell Paul Daruwala Individual 02. Oct 19 02. Oct 19 -3,295 €1.72 €-5,655
03. Oct 19 Sell Neil Abdollahian Individual 01. Oct 19 01. Oct 19 -7,284 €1.81 €-13,198
01. Oct 19 Sell Jessica Oien Individual 27. Sep 19 27. Sep 19 -1,001 €1.70 €-1,701
27. Sep 19 Buy Jeffrey Stein Individual 24. Sep 19 24. Sep 19 52,500 €1.73 €90,982
23. Mar 20 Buy James Levine Individual 24. Sep 19 24. Sep 19 30,000 €1.73 €52,025
X
Management checks
We assess Cidara Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cidara Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

20D News

Simply Wall St News

20D Company Info

Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Details
Name: Cidara Therapeutics, Inc.
20D
Exchange: DB
Founded: 2012
$91,277,856
40,513,558
Website: http://www.cidara.com
Address: Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive,
Suite 101,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CDTX Common Shares Nasdaq Global Market US USD 15. Apr 2015
DB 20D Common Shares Deutsche Boerse AG DE EUR 15. Apr 2015
BRSE 20D Common Shares Berne Stock Exchange CH CHF 15. Apr 2015
Number of employees
Current staff
Staff numbers
68
Cidara Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:12
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/04
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.